CA2539914A1 - Compositions a petites molecules et procedes destines a augmenter l'efficacite d'un medicament au moyen de ces compositions - Google Patents

Compositions a petites molecules et procedes destines a augmenter l'efficacite d'un medicament au moyen de ces compositions Download PDF

Info

Publication number
CA2539914A1
CA2539914A1 CA002539914A CA2539914A CA2539914A1 CA 2539914 A1 CA2539914 A1 CA 2539914A1 CA 002539914 A CA002539914 A CA 002539914A CA 2539914 A CA2539914 A CA 2539914A CA 2539914 A1 CA2539914 A1 CA 2539914A1
Authority
CA
Canada
Prior art keywords
conjugate
alkyl
aryl
arylureido
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002539914A
Other languages
English (en)
Inventor
Angelo John Castellino
Simon Eric Aspland
Carlo Ballatore
Joel Desharnais
Michael James Newman
Chengzao Sun
Peter Wirsching
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acidophil LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2539914A1 publication Critical patent/CA2539914A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0404—X-ray contrast preparations containing barium sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Dans certains modes de réalisation, l'invention concerne des compositions et des procédés destinés à augmenter l'efficacité d'un médicament. Les conjugués ajoutés sont dans certains modes de réalisation, destinés à des compositions et à des procédés de traitement d'une variété de maladies et sont représentés par la formule (1) : D - L - S ou la formule (2) : D - L - S~. Dans ces formules, D représente une fraction médicamenteuse; L, qui peut être présent ou non, représente une fraction liante de non libération; S représente un substrat pour une kinase, autre que l'hexokinase, la kinase protéique ou la kinase lipidique; et S' représente un substrat pour une phosphotransférase, autre que l'hexokinase, la kinase protéique ou la kinase lipidique.
CA002539914A 2003-09-22 2004-09-22 Compositions a petites molecules et procedes destines a augmenter l'efficacite d'un medicament au moyen de ces compositions Abandoned CA2539914A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50532503P 2003-09-22 2003-09-22
US60/505,325 2003-09-22
US58183504P 2004-06-22 2004-06-22
US60/581,835 2004-06-22
PCT/US2004/031147 WO2005030258A2 (fr) 2003-09-22 2004-09-22 Compositions a petites molecules et procedes destines a augmenter l'efficacite d'un medicament au moyen de ces compositions

Publications (1)

Publication Number Publication Date
CA2539914A1 true CA2539914A1 (fr) 2005-04-07

Family

ID=34396244

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002539914A Abandoned CA2539914A1 (fr) 2003-09-22 2004-09-22 Compositions a petites molecules et procedes destines a augmenter l'efficacite d'un medicament au moyen de ces compositions

Country Status (5)

Country Link
EP (1) EP1689439A2 (fr)
JP (1) JP2007522094A (fr)
AU (1) AU2004275770A1 (fr)
CA (1) CA2539914A1 (fr)
WO (1) WO2005030258A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
EP1576138B1 (fr) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-MÉTHYL-NUCLEOSIDES EN COMBInaISON AVEC l'INTERFÉRON ET MUTATION DE FLAVIVIRIDAE
US8138361B2 (en) 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2694481T3 (es) 2008-05-23 2018-12-21 The University Of British Columbia Fármacos modificados para su uso en nanopartículas liposomales
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (fr) 2010-04-12 2011-10-20 Academia Sinica Puces au glycane pour la recherche par criblage haut débit de virus
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
ES2671478T3 (es) 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
US9732111B2 (en) 2012-11-19 2017-08-15 Merck Sharp & Dohme Corp. 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3013365B1 (fr) 2013-06-26 2019-06-05 Academia Sinica Antigènes rm2 et leur utilisation
WO2014210564A1 (fr) 2013-06-27 2014-12-31 Academia Sinica Conjugués de glycane et leur utilisation
CA2923579C (fr) 2013-09-06 2023-09-05 Academia Sinica Activation des cellules humaines inkt a l'aide de glycolipides ayant des groupes glycolsyles modifies
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149037A4 (fr) 2014-05-27 2018-01-10 Academia Sinica Glycoanticorps anti-her2 et leurs utilisations
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
KR20230033737A (ko) 2014-05-27 2023-03-08 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
WO2016040369A2 (fr) 2014-09-08 2016-03-17 Academia Sinica Activation des cellules inkt humaines par des glycolipides
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (fr) 2015-01-24 2016-07-28 Academia Sinica Nouveaux composes conjugues de glycane et leurs methodes d'utilisation
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
JP2021523945A (ja) * 2018-05-15 2021-09-09 インテルク ペプチド セラピューティクス リミテッド 活性化剤
WO2019218016A1 (fr) * 2018-05-15 2019-11-21 Interk Peptide Therapeutics Limited Agent d'activation de peptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59083A (en) * 1979-01-10 1983-12-30 Israel Marcus Pharmaceutical composition containing thymidine and a salicyclic acid derivative as a solubilizing agent therefor
US5608049A (en) * 1995-03-10 1997-03-04 Bristol-Myers Squibb Company Preparation of d4T from 5-methyluridine
US5723589A (en) * 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds

Also Published As

Publication number Publication date
WO2005030258A2 (fr) 2005-04-07
AU2004275770A1 (en) 2005-04-07
JP2007522094A (ja) 2007-08-09
EP1689439A2 (fr) 2006-08-16
WO2005030258A3 (fr) 2005-09-22

Similar Documents

Publication Publication Date Title
CA2539914A1 (fr) Compositions a petites molecules et procedes destines a augmenter l'efficacite d'un medicament au moyen de ces compositions
US20050148534A1 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US9695211B2 (en) Method for the synthesis of phosphorus atom modified nucleic acids
AU2012223012C1 (en) Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
WO2003062256A1 (fr) Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
US20080132525A1 (en) Inhibitors of DNA Methyltransferase
US7019135B2 (en) Anti-viral pyrimidine nucleoside analogues
WO2005035003A2 (fr) Compositions et procedes destines a augmenter l'efficacite d'un medicament
NZ500881A (en) Anti-viral pyrimidine nucleoside analogues
KR20070087687A (ko) 항증식 활성을 갖는 피리미도 화합물
EP2049543A1 (fr) Inhibiteurs amines acycliques de la 5'-méthylthioadénosine phosphorylase et nucléosidase
US9463200B2 (en) Cell-penetrating oligonucleotides
WO2003051898A1 (fr) Banques de nucleosides et composes rares, et utilisations preferees comme agents anticancereux et antiviraux
US4975434A (en) Antiviral and anticancer cyclopentenyl cytosine
US6372725B1 (en) Specific lipid conjugates to nucleoside diphosphates and their use as drugs
CA2446620A1 (fr) Nucleosides antiviraux
US9902752B2 (en) 5-fluorouracil derivatives
KR20050109939A (ko) 뉴클레오티드 지질 에스테르 유도체
US20110028497A1 (en) Novel derivatives of purinic and pyrimidinic antiviral agents and use thereof as potent anticancer agents
US20190322693A1 (en) Nucleoside analogues and methods of use thereof
US7217815B2 (en) 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents
Koszalka et al. 6-N-substituted derivatives of adenine arabinoside as selective inhibitors of varicella-zoster virus
Kumar 5-Bromo (or chloro)-6-azido-5, 6-dihydro-2′-deoxyuridine and-thymidine derivatives with potent antiviral activity
US6825348B2 (en) Antiviral compounds
AU724124B2 (en) Pyrimidopyrimidine compounds

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20080922